Microsatellite polymorphism of steroid hormone synthesis gene CYP11A1 is associated with advanced prostate cancer

International Journal of Cancer

Volumn 110, Issue 1, 2004, Pages 140-144

  Kumazawa, Teruaki ^a   Tsuchiya, Norihiko ^a   Wang, Lizhong ^a   Sato, Kazunari ^a   Kamoto, Toshiyuki ^b   Ogawa, Osamu ^b   Nakamura, Akira ^a   Kato, Tetsuro ^a   Habuchi, Tomonori ^a  

^a AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Benign prostatic hyperplasia; CYP11A1; P450scc; Polymorphism; Prostate cancer; Steroid hormone synthesis

Indexed keywords

ANDROSTENEDIONE; CYTOCHROME P450; CYTOCHROME P450 11A1; ESTRADIOL; ESTRONE; MICROSATELLITE DNA; PRASTERONE; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALLELE; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA POLYMORPHISM; ESTRADIOL BLOOD LEVEL; ESTRONE BLOOD LEVEL; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; RISK ASSESSMENT; STEROIDOGENESIS; TESTOSTERONE BLOOD LEVEL;

AGED; AGED, 80 AND OVER; CHOLESTEROL SIDE-CHAIN CLEAVAGE ENZYME; GONADAL STEROID HORMONES; HUMANS; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, GENETIC; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 1942484465     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20070     Document Type: Article

References (30)

1. Tayler JD, Holmes TM, Swanson GM. Descriptive epidemiology of prostate cancer in metropolitan Detroit. Cancer 1994;73:1704-7.
2. Oishi K, Yoshida O, Schroeder FH. The geography of prostate cancer and its treatment in Japan. Cancer Surv 1995;23:267-80.
3. Partin AW, Coffey DS. The molecular biology, endocrinology, and physiology of the prostate and seminal vesicles. In: Walsh PC, Retic AB, Vaughan Jr ED, Wein AJ, eds. Canbell's urology, 7th ed. Philadelphia: W.B. Saunders Co., 1998. 1381-428p.
4. Latil AG, Azzouzi R, Cancel GS, Guillaume EC, Cochan-Priollet B, Berthon PL, Cussenot O. Prostate carcinoma risk and allelic variants of genes Involved in androgen biosynthesis and metabolism pathways. Cancer 2001;92:1130-7.
5. Morohashi K, Sogawa K, Omura T, Fujii Y. Gene structure of human cytochrome P-450(SCC), cholesterol desmolase. J Biochem 1987;101:879-87.
6. Schwarz D, Kisselev P, Pfeil W, Pisch S, Bornscheuer U, Schmid RD. Evidence that nonbilayer phase propensity of the membrane is important for the side chain cleavage activity of cytochrome P450SCC (CYP11A1). Biochemistry 1997;36:14262-70.
7. Franks S, Gharani N, Waterworth D, Batty S, White D, Williamson R, McCarthy M. Genetics of polycystic ovary syndrome. Mol Cell Endocrinol 1998;145:123-8.
8. Durocher F, Morissette J, Simard J. Genetic linkage mapping of the CYP11A1 gene encoding the cholesterol side-chain cleavage P450scc close to the CYP11A1 gene and D15S204 in the chromosome-15q22.33-q23 region. Pharmacogenetics 1998;8:49-53.
9. Moore CCD, Brentano ST, Miller WL. Human P450scc gene transcription is induced by cyclic AMP and repressed by 12-o-tetradecanoylphorbol-13-acetate and A23187 through independent cis element. Mol Cell Biol 1990;10:6013-23.
10. Gharani N, Waterworth DM, Batty S, White D, Gilling-Smith C, Conway GS, McCarthy M, Franks S, Williamson R. Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. Hum Mol Genet 1997;6:397-402.
11. Diamanti-Kandarakis E, Bartzis MI, Bergiele AT, Tsianateli TC, Kouli CR. Microsatellite polymorphism (tttta)n at -528 base pairs of gene CYP11Aa influences hyperandrogenemia in patients with polycystic ovary syndrome. Fertil Steril 2000;73:735-41.
12. Nolan CJ, Payne AH. Genotype at the P450scc locus determines differences in the amount of P450scc protein and maximal testosterone production in mouse leydig cells. Mol Endocrinol 1990;4:1459-64.
13. Habuchi T, Liqing Z, Suzuki T, Sasaki R, Tsuchiya N, Tachiki H, Shimoda N, Satoh S, Sato K, Kakehi Y, Kamoto T, Ogawa O, et al. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res 2000;60:5710-3.
14. Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis 2000;22:427-33.
15. Makridakis NM, Reichardt JK. Molecular epidemiology of hormone-metabolic loci in prostate cancer. Epidemiol Rev 2001;23:24-9.
16. The Japanese Urological Association and the Japanese Society of Pathology. General rules for clinical and pathological studies on prostate cancer, 3rd ed. Tokyo, Japan: Kanahara-Shuppan Co., 2001.
17. International Union Against Cancer. Urological tumors: prostate. In: Hermanek P, Sobin LH, eds. TNM classification of malignant tumors, 4th ed. Berlin: Springer-Verlag, 1992. 141-4p.
18. Gleason DF, the VACURG. Histological grading and clinical staging of prostate carcinoma. In: Tannenbaum M. Urologic pathology. Philadelphia: Lea & Feiger, 1977. 171-97p.
19. Ohori M, Wheeler TM, Scardino PT. The new American joint committee on cancer and international union against cancer TNM classification of prostate cancer. Cancer 1994;74:104-14.
20. San Millan JL, Sancho J, Calvo RM, Escobar-Morreale HF. Role of the pentanucleotide (tttta)(n) polymorphism in the promoter of the CYP11a gene in the pathogenesis of hirsutism. Fertil Steril 2001;75:797-802.
21. Urbanek M, Legro RS, Driscoll DA, Azziz R, Ehrmann DA, Norman RJ, Strauss JF, Spielman RS, Dunaif A. Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc Natl Acad Sci U S A 1999;96:8573-8.
22. Daneshmand S, Weitsman SR, Navab A, Jakimiuk AJ, Magoffin DA. Overexpression of theca-cell messenger RNA in polycystic ovary syndrome does not correlate with polymorphisms in the cholesterol side-chain cleavage and 17alpha-hydroxylase/C17-20 lyase promoter. Fertil Steril 2002;77:274-80.
23. Storlie JA, Bucker JA, Wiseman GA, Burch PA, Hartmann LC, Richardson RL. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer 1995;76:96-100.
24. Kobayashi T, Jo Y, Ikegami M, Furukawa Y, Morioka M, Tanaka H. Clinical evaluation of low dose glucocorticoid therapy for hormone-refractory prostate cancer. Int J Urol 2000;91:479-84.
25. Nishiyama T, Terunuma M. Hormone/Antihormone withdrawal and dexamethasone for hormone-refractory prostate cancer. Int J Urol 1998;5:44-7.
26. Weitzman AL, Shelton G, Zuech N, Owen CE, Judge T, Benson M, Sawczuk I, Katz A, Olsson CA, Bagiella E, Pfaff C, Newhouse JH, et al. dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer. J Urol 2000;163:834-7.
27. Nishimura K, Nonomura N, Yasunaga Y, Takaha N, Inoue H, Sugao H, Yamaguchi S, Ukimura O, Miki T, Okuyama A. Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer 2000;89:2570-6.
28. Wade DP, Clarke JG, Lindahl GE, Liu AC, Zyson BR, Meer K, Schwertz K, Lawn RM. 5′ control region of the apolipoprotein(a) gene and members of the related plasminogen gene family. Proc Natl Acad Sci U S A 1993;90:1369-73.
29. Content A, Dittmer A, Koch MC, Roth J, Dobbelstein M. A polymorphic microsatellite that mediates induction of PIG3 by p53. Nat Genet 2002;30:315-20.
30. Hum DW, Staels B, Black SM, Miller WL. Basal transcriptional activity and cyclic adenosine 3′, 5′-monophosphate responsiveness of the human cytochrome P450scc promoter transfected into MA-10 Leydig cells. Endcrinology 1993;132:546-52.